Enhanced Absorption of Nasulin™ an Ultrarapid-Acting Intranasal Insulin Formulation Using Single Nostril Administration in Normal Subjects

摘要

BackgroundThis pharmacokinetic (PK) study was designed to investigate the maximum intranasal insulin dose that could be achieved by repeated doses in a single nostril of a nasal spray of recombinant regular human insulin 1% in combination with cyclopentadecalactone (CPE-215) 2%, a compound that enhances absorption of molecules across mucous membranes (Nasulin™, CPEX Pharmaceuticals, Inc.).